Allergies
Arthritis
Arthritis and Acupuncture
Arthritis and Gene Therapy
Therapy and Bone Repair
About Arthritis
Osteoarthritis
Rheumatoid Arthritis
Automimmune diseases
Autoimmune Diseases
About Autoimmune Diseases
Lupus Chinese Medicines
Lupus Treatments
Thrush primary immunodeficiency
Thrush
Bladder problems
Transurethral Resection
About Bladder Problems
Overactive Bladder
Treating Overactive Bladder
Urinary Incontinence Causes
Urinary Incontinence
Urinary Tract Infections and Diet
Urinary Tract Infections
Blood and vascular disorders
Warfarin and Vitamin K
About Blood and Vascular Disorders
Varicose Veins Risks
Varicose Veins
Waldenstroms
Cancer
HRT and Breast Cancer
Research and Breast Cancer
Food Prevention
About Cancer
Kidney Cancer
Kidney Tumors
Leiomyosarcoma
Leukemia Survival
Leukemia
Liver Cancer
Lung Cancer New Treatments
Lung Cancer
Lymphoma Actually Two Forms of Cancer
Lymphoma
Milk Treatment
Mouth Cancer
Oral Cancer Treatment
Ovarian Cancer
Ovarian Cancers Gene Mutations
Pancreatic Cancer Protein Tumor Fighter
Pancreatic Cancer
Prostate Cancer Treatment
Prostate Cancer
Testicular Cancer Transplants
Testicular Cancer
Throat Cancer Your Voice
Throat Cancer
Uterine Cancer Detection
Uterine Cancer
Cholesterol
Diabetes
Diabetes in Children
Diabetes Insipidus
Diabetes Risk
Diabetic Retinopathy
About Diabetes
Peripheral Neuropathy
Type 1 Diabetes
Type 1 Treatment
Type 2 Diabetes
Type 2 Treatment
Erectile dysfunction
Headaches
Heart problems
Heartburn and gerd
Herpes
Hypertension
Causes and Symptoms
Fighting Hypertension
Angiostensin II Blockers
Hypertension Medications
Hypertension-Headaches
About Hypertension
Preventing Hypertension
Intestinal problems
Crohn's Disease
Hormone Therapy
About Intestinal Problems
Irritable Bowel Syndrome
Ulcerative Colitis Self Management
Ulcerative Colitis
Lung diseases
Obesity
Osteoporosis
Pain
About Pain
New Class of Anti-Inflammatory Painkiller
Nervous System
Pain Management Cycles
Pain Management evaluation
Prostate problems
Psychiatric disorders
Alcohol and Dementia
New Molecule to Reduce Amyloid Depostis
Screening Tools for Alzheimers
Blood Flow and Alzheimers
Alzheimer's and Caregivers
Anemia & Dementia
Anxiety and Perception
Child Abuse and Depression
Anxiety and the Adolescent
Coping with Depression
The Elderly
About Psychiatric Disorders
Parkinsons Disease Dopamine
Parkinson's Disease
Teen Health & Depression
Teenage Depression
Salivary glands
Skin disorders
Acne Causes
Laser Treatments for Acne
About Skin Disorders
Psoriasis Treatment
Psoriasis
Rosacea Symptoms
rosacea
Skin Cancer Survival
Skin Cancer
Treatment Options
Sleep
Drugs Sleep Deprivation
About Sleep
Insomnia and Alcohol
Insomnia and Tea
Insomnia
Sleep Disorders Narcolepsy
Sleep Disorders
Students Sleep Deprivation
Turner syndrome
Wellness
Womens health
Reluctance to Seek Help for FSD
About Womens Health
Intranasal Apomorphine HCl
Menopause Symptom Relief
Uterine Fibroids Treatment
Uterine Fibroids
|
Exciting Breakthrough for the Treatment of Allergic Conditions: The GE2 MoleculeA recent study conducted by scientists at the University of California, Los Angeles (UCLA) and by the University of New Mexico (UNM), concludes that an experimental therapy has succeeded in halting allergic reactions in mice. Their findings are reported in the in the May 2002 issue of Nature Medicine and supported by the National Institute of Allergy and Infectious Diseases (NIAID).According to Anthony S. Fauci, M.D., Director of NIAID, "The prevalence of allergic disease has increased significantly in recent decades, and there simply are not many promising therapeutic strategies out there. We hope that NIAID's continued support of research into the mechanisms of allergy will lead to other innovative concepts like this one." The UCLA-UNM study group used a specially designed molecule, GE2, to link two receptors on the key immune system cells that trigger allergy reactions. They discovered that the process of cross-connecting these two receptor molecules effectively "short-circuits" the types of symptoms that can result in the onset of asthma, hay fever and, in extreme cases, life-threatening anaphylaxis. Fauci concludes: "This work represents an entirely new approach to treating allergic diseases." His observations are endorsed by Marshall Plaut, M.D., Chief of NIAID's Allergic Mechanisms Section, who states: "This research does what science is supposed to do . . . the researchers (have) succeeded in translating a scientific observation into a clever therapeutic idea." The GE2 molecule acts on two types of immune cells—mast cells and basophils—both of which are central to allergic reactions. GE2 works by binding itself to the receptor molecules on the mast cells and basophils, thus controlling the release of histamine, which can trigger a reaction in allergy sufferers. Senior study author, Andrew Saxon, M.D., director of the UCLA Asthma, Allergy, and Immunologic Disease Center, offers the following graphic analogy: "One of these receptor molecules is like a gas pedal: it makes the allergic reaction go. The other receptor molecule is like a brake. However, in this case, the brake only works when coupled with the gas pedal. Therefore, we constructed GE2 so that one end 'steps on' the brake while the other end binds to the gas pedal. This cross-linking slows or stops the allergic reaction". The conclusion? The application of GE2 significantly reduced allergic skin reactions, in tests on mice. Further, in laboratory tests on human mast cells and basophils, a clear pattern emerged: the higher the dose of GE2, the lower the level of histamine released by cells stimulated by an allergen. The implications? As research into GE2 therapy is still in its infancy, wider animal trials will be required before this innovative approach can be tested on humans. The possibilities, however, for treating conditions such as asthma, allergic rhinitis (hay fever), chronic urticaria, angioedema, anaphylaxis and other allergic diseases are clearly apparent. Although the current generic structure of the GE2 molecule works indiscriminately to block reactions to all allergens, the potential for refinement and development is immense. Dr. Saxon, for example, proposes the possibility of designing a GE2 to contain a specific allergen targeted at blocking a particular allergic reaction. Much, however, remains to be explored in the area of GE2 therapy for treating allergic diseases. Resource National Institutes of Health. (2002). Experimental therapy stops allergic reactions in mice. Retrieved July 10, 2002, from www.nih.gov/news/pr/apr2002/niaid-30.htm. |
Ads by Yahoo!
Claritin Coupons
Relieve Your Worst Allergy Symptoms Get Claritin® Coupons. www.Claritin.com My Allergy Guide Information To Help You Understand, Manage And Relieve Your Allergies Zyrtec.com Nasal Allergy Treatment Review Nasal Allergy Symptoms & Treatment Options. www.Nasal-Allergies.com |
|
Home
| About Us
| Terms of Use
| Privacy & Security
| Site Map
| © morefocus group, inc. | |
